B
CRL icon

Barings’s Charles River Laboratories CRL Stock Holding History

Barings’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8,900
Closed -$742K – 877
2016
Q3 		$742K Hold
8,900
– – 0.02% 500
2016
Q2 		$734K Hold
8,900
– – 0.02% 561
2016
Q1 		$676K Hold
8,900
– – 0.02% 598
2015
Q4 		$715K Hold
8,900
– – 0.02% 566
2015
Q3 		$565K Sell
8,900
-7,800
-47% -$560K 0.01% 596
2015
Q2 		$1.18M Buy
16,700
+13,100
+364% +$969K 0.04% 464
2015
Q1 		$285K Hold
3,600
– – 0.01% 829
2014
Q4 		$229K Hold
3,600
– – 0.01% 863
2014
Q3 		$215K Sell
3,600
-38,400
-91% -$2.2M ﹤0.01% 895
2014
Q2 		$2.25M Buy
42,000
+38,100
+977% +$2.09M 0.07% 296
2014
Q1 		$235K Hold
3,900
– – 0.01% 847
2013
Q4 		$207K Buy
+3,900
New +$196K 0.01% 867

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Barings's CRL Position: Q4 2016 in Review

Barings sold out of Charles River Laboratories (CRL) in Q4 2016, closing a stake of 8,900 shares — an estimated $742K sold.

Barings first reported a position in CRL in Q4 2013 and held it in 12 quarters. The position peaked at $2.25M in Q2 2014. 297 funds tracked by Wall St. Rank hold CRL as of Q4 2016.

  • Barings reported no remaining Charles River Laboratories position as of Q4 2016 after selling out during the quarter.
  • Barings sold 8,900 Charles River Laboratories shares in Q4 2016, an estimated $742K.
  • Barings first reported a position in Charles River Laboratories in Q4 2013 and held it in 12 quarters.
  • Barings's Charles River Laboratories position peaked at $2.25M in Q2 2014.
  • 297 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2016.

Based on Barings's 13F filing for Q4 2016, filed 15 Feb 2017.